These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 21510996)

  • 1. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
    Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.
    Andersson KM; Paltiel AD; Owens DK
    Vaccine; 2011 Aug; 29(36):6107-12. PubMed ID: 21736912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential impact of an HIV vaccine with limited protection on HIV incidence in Thailand: a modeling study.
    Nagelkerke NJ; Hontelez JA; de Vlas SJ
    Vaccine; 2011 Aug; 29(36):6079-85. PubMed ID: 21718745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
    Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
    Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
    Gray RT; Ghaus MH; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012.
    Moodley N; Gray G; Bertram M
    BMC Public Health; 2016 Apr; 16():330. PubMed ID: 27079900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
    Schneider K; Kerr CC; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.
    de Montigny S; Adamson BJS; Mâsse BR; Garrison LP; Kublin JG; Gilbert PB; Dimitrov DT
    Sci Rep; 2018 Apr; 8(1):6066. PubMed ID: 29666455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
    Juusola JL; Brandeau ML; Owens DK; Bendavid E
    Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
    Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
    PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries.
    Harmon TM; Fisher KA; McGlynn MG; Stover J; Warren MJ; Teng Y; Näveke A
    PLoS One; 2016; 11(1):e0146387. PubMed ID: 26731116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
    Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
    J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of a targeted age-based West Nile virus vaccination program.
    Shankar MB; Staples JE; Meltzer MI; Fischer M
    Vaccine; 2017 May; 35(23):3143-3151. PubMed ID: 28456529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.
    Long EF; Brandeau ML; Owens DK
    Vaccine; 2009 Aug; 27(39):5402-10. PubMed ID: 19591796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
    Long EF; Brandeau ML; Owens DK
    Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.